Quoin Pharmaceuticals Reports Positive Interim Phase 2/3 Data for QRX003 in Netherton Syndrome
Ashburn, Va. – August 28, 2026 Quoin Pharmaceuticals announced positive interim results from the ongoing Phase 2/3 CL-QRX003-004 study...
Retina
Advertisement
Roche’s Vabysmo Enables Extended 20-Week Dosing in PCV Patients
Basel, Switzerland – August 28, 2026 Roche announced new two-year results from the Phase IIIb/IV SALWEEN study evaluating Vabysmo®...
Harrow Reports 58% Reduction in Patient-Reported Discomfort with IHEEZO®
NASHVILLE, Tennessee, August 20, 2026 Harrow, Inc. announced positive results from a prospective, randomized contralateral-eye study evaluating IHEEZO® (chloroprocaine...
Outlook Therapeutics Targets U.S. Launch of FDA-Approved LYTENAVA
ISELIN, N.J., August 14, 2026 Outlook Therapeutics, Inc. is advancing preparations for the U.S. commercial launch of LYTENAVA™ (bevacizumab-vikg)...
Ocugen Receives FDA RMAT Designation for OCU410 in Geographic Atrophy
MALVERN, Pa., July 29, 2026 Ocugen, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
Advertisements
Outlook Therapeutics Secures FDA Approval for LYTENAVA™
ISELIN, N.J., July 24, 2026 Outlook Therapeutics has achieved a major regulatory milestone after the U.S. Food and Drug...
Belite Bio Reports Positive Phase 3 Tinlarebant Data at ASRS 2026
SAN DIEGO, July 20, 2026 Belite Bio, Inc. (NASDAQ: BLTE) announced additional positive secondary endpoint data from its Phase...
Harrow Highlights New IHEEZO and BYOOVIZ Clinical Evidence at ASRS 2026
NASHVILLE, Tenn., July 20, 2026 Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,...
REGENXBIO Reports Positive Long-Term Gene Therapy Results
ROCKVILLE, Md., July 18, 2026 REGENXBIO Inc. has announced positive long-term clinical data for its investigational one-time gene therapy,...
4DMT Reports Positive 2-Year PRISM Phase 2b Data for 4D-150
EMERYVILLE, Calif., July 18, 2026 4D Molecular Therapeutics (4DMT) announced positive two-year results from its PRISM Phase 2b clinical...
Advertisement
